Abstract
Objective: Antiphospholipid antibodies (APLs) could be associated with an increased risk of vascular pathologies in systemic scleroderma. The aim of our study was to search for APLs in patients affected by systemic scleroderma and to evaluate their involvement in the clinical manifestations of this disease. Materials and Methods: We conducted a cross-sectional descriptive study, from January 2009 until August 2010, with patients received at the Department of Dermatology (Dakar, Senegal). Blood samples were taken at the hematology laboratory and were analyzed for the presence of APLs. Results: Forty patients were recruited. Various types of either isolated or associated APLs were found in 23 patients, i.e. 57.5% of the study population. The most frequently encountered antibody was IgG anti-β2 GPI (37.5% of the patients), followed by anticardiolipins (17.5%) and lupus anticoagulants (5%). No statistically significant association of positive antiphospholipid-related tests to any of the scleroderma complications could be demonstrated. Conclusion: A high proportion of patients showing association of systemic scleroderma and APLs suggests the presence of a morbid correlation between these 2 pathologies. It would be useful to follow a cohort of patients affected by systemic scleroderma in order to monitor vascular complications following confirmation of the presence of antiphospholipid syndrome. Conflict of interest:None declared.
Highlights
We read with great interest the article by Touré and colleagues published in a recent issue of your journal, entitled “Antiphospholipid Antibodies and Systemic Scleroderma”
antiphospholipid syndrome (APS) is being increasingly recognized as an important cause of renal damage due to thrombosis at any location within the renal vasculature [5]
The term “APS nephropathy (APSN)” refers to the various renal pathologies caused by vascular lesions in the glomeruli, arterioles, and/or interlobular arteries in patients with aPLs [5,6,7]
Summary
We read with great interest the article by Touré and colleagues published in a recent issue of your journal, entitled “Antiphospholipid Antibodies and Systemic Scleroderma”. APS is being increasingly recognized as an important cause of renal damage due to thrombosis at any location within the renal vasculature [5]. The term “APSN” refers to the various renal pathologies caused by vascular lesions in the glomeruli, arterioles, and/or interlobular arteries in patients with aPLs [5,6,7]. From the nephrology point of view, this small-vessel, vaso-occlusive nephropathy may present with hypertension, acute and/or chronic renal failure, and often a low-grade proteinuria clinically [8,9,10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
